https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-02-01 / Curr. Opin. Mol. Ther. 2006 Feb;8(1):46-51
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-02-01 / Curr. Opin. Mol. Ther. 2006 Feb;8(1):46-512006-02-01 00:00:002019-02-15 09:00:02Novel immunotherapeutic approaches to glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-02-01 / HBPD INT 2006 Feb;5(1):22-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-02-01 / HBPD INT 2006 Feb;5(1):22-72006-02-01 00:00:002019-02-15 09:17:43Recent advances in heat shock protein-based cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-02-01 / Int. J. Cancer 2006 Feb;118(3):658-67
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-02-01 / Int. J. Cancer 2006 Feb;118(3):658-672006-02-01 00:00:002020-06-23 09:36:57A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-02-01 / Clin. Cancer Res. 2006 Feb;12(3 Pt 1):878-87
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-02-01 / Clin. Cancer Res. 2006 Feb;12(3 Pt 1):878-872006-02-01 00:00:002019-02-15 08:48:35Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-02-01 / Cancer Gene Ther. 2006 Feb;13(2):182-93
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-02-01 / Cancer Gene Ther. 2006 Feb;13(2):182-932006-02-01 00:00:002006-02-01 00:00:00Preparation of apoptotic tumor cells with replication-incompetent HSV augments the efficacy of dendritic cell vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-02-01 / Clin Cancer Res 2006 Feb;12(3 Pt 1):869-77
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-02-01 / Clin Cancer Res 2006 Feb;12(3 Pt 1):869-772006-02-01 00:00:002006-02-01 00:00:00Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-21 / World J. Gastroenterol. 2006 Jan;12(3):473-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-21 / World J. Gastroenterol. 2006 Jan;12(3):473-82006-01-21 00:00:002019-02-15 08:38:17Heat-shocked tumor cell lysate-pulsed dendritic cells induce effective anti-tumor immune response in vivo
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-18 / Vaccine 2006 Feb;24(7):887-96
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-18 / Vaccine 2006 Feb;24(7):887-962006-01-18 00:00:002019-02-15 08:37:42Novel vaccines for the treatment of chronic HBV infection based on mycobacterial heat shock protein 70
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-18 / Immunobiology 2006;211(1-2):29-36
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-18 / Immunobiology 2006;211(1-2):29-362006-01-18 00:00:002019-02-15 08:44:42Immunization with antigen-pulsed dendritic cells significantly improves the immune response to weak self-antigens
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2006-01-17 / Ann. Oncol. 2006 Apr;17(4):563-70
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2006-01-17 / Ann. Oncol. 2006 Apr;17(4):563-702006-01-17 00:00:002019-02-15 09:19:51Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG
